Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.

Abstract: The present invention relates to a method for preparing an itraconazole-containing solid dispersion. The itraconazole-containing solid dispersion according to the preparing method of the present invention has both improved solubility and rapid dissolution rate so that it has an excellent bioavailability. The itraconazole-containing solid dispersion of the present invention is also independent of pH variation of human stomach so that it can minimize the absorption variation of intra- and inter-individuals. In addition, the itraconazole-containing solid dispersion according to the preparing method of the present invention is stable for a long time. The present invention also provides an economical and environment-friendly method for manufacturing an itraconazole-containing composition because the method adds a lactic acid in a solution comprising itraconazole to decrease the amount of an organic solvent needed to dissolve itraconazole.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.

Abstract: The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.

Abstract: The present invention provides a method for producing a film which contains a tasteless donepezil-free base, has an appropriate size and thickness, has flexibility for providing stability when handled so as to not easily tear, and has a uniformly dispersed donepezil-free base. In addition, the present invention provides a film containing the donepezil-free base produced through the method.

Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.

Abstract: The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects.

Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.

Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.

Abstract: The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil free base-containing film prepared from the method.

Abstract: The present invention relates to a composition and method for treating or preventing white spot syndrome virus of arthropod. The present invention is based on using Artemisia japonica extract, and preferably, a mixture of Artemisia japonica extract and Saururus chinensis extract as effective agent. More preferably, the present invention provides a composition for treating or preventing white spot syndrome virus, comprising Artemisia japonica extract and Saururus chinensis extract which are coated by a polymer. The present invention also provides a method for treating or preventing white spot syndrome virus of arthropod, using Artemisia japonica extract and Saururus chinensis extract which are coated by a polymer.

Abstract: Disclosed is a pharmaceutical composition containing losartan carboxylic acid and a preparing method thereof. The pharmaceutical composition has the improved dissolution speed and dissolution rate, and the reduced variation in dissolution depending on the pH of a medium.

Abstract: The present invention relates to esomeprazole free base or its alkali salt-containing composition which stability is improved and is easy to manufacture.

Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.

Abstract: The present invention relates to a method for preparing an itraconazole-containing solid dispersion. The itraconazole-containing solid dispersion according to the preparing method of the present invention has both improved solubility and rapid dissolution rate so that it has an excellent bioavailability. The itraconazole-containing solid dispersion of the present invention is also independent of pH variation of human stomach so that it can minimize the absorption variation of intra- and inter-individuals. In addition, the itraconazole-containing solid dispersion according to the preparing method of the present invention is stable for a long time. The present invention also provides an economical and environment-friendly method for manufacturing an itraconazole-containing composition because the method adds a lactic acid in a solution comprising itraconazole to decrease the amount of an organic solvent needed to dissolve itraconazole.

Abstract: The present invention relates to a composition and method for treating or preventing white spot syndrome virus of arthropod. The present invention is based on using Artemisia japonica extract, and preferably, a mixture of Artemisia japonica extract and Saururus chinensis extract as effective agent. More preferably, the present invention provides a composition for treating or preventing white spot syndrome virus, comprising Artemisia japonica extract and Saururus chinensis extract which are coated by a polymer. The present invention also provides a method for treating or preventing white spot syndrome virus of arthropod, using Artemisia japonica extract and Saururus chinensis extract which are coated by a polymer.

Abstract: The present invention relates to a composition comprising sibutramine free base. The present invention provides a solid dispersion wherein sibutramine free base, acid and hydrophilic polymer are uniformly dispersed and a manufacturing method thereof. The composition of the present invention has improved dissolution rate compared to conventional compositions containing sibutramine free base or sibutramine hydrochloride, and is also stable during storage and can be easily mass-produced.

Abstract: The present invention relates to an enteric coated granule prepared by coating lactic acid bacteria-containing seed with a water-miscilble coating material and then, if desired, subjecting the first coated product to the second coating with a controlled-release coating material.

Abstract: The present invention relates to a microgranule prepared by using an alkali compound as a stabilizer for a 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivative having the following formula (1), which is a very effective antiulcerative but highly unstable under acidic conditions, and by using a water-soluble polymer as a binding agent. in which X, R1, R2, R3, R4 and R5 are defined as described in the specification.